Denmark has cut its 2025 economic growth forecast to 1.4% from 3%, citing weaker prospects for pharmaceutical giant Novo ...

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

Denmark cuts 2025 growth forecast as Novo Nordisk slowdown and US tariffs raise fears of over-reliance on pharma.

Denmark has cut its 2025 economic growth forecast to 1.4% from 3%, citing weaker prospects for pharmaceutical giant Novo Nordisk and tariffs on Danish goods exported to the US, the country's economy ...

Novo Nordisk's (NVO) challenges and higher U.S. tariffs are cited as Denmark cuts 2025 growth forecast to 1.4%. Read more here.

Investing.com -- Novo Nordisk A/S has canceled contracts for new recruits just days or weeks before their start dates as part of broader cost-cutting measures, Bloomberg reports.

--Denmark cut its 2025 GDP growth forecast to 1.4% from 3% amid weaker prospects for pharmaceutical giant Novo Nordisk and U.S. tariff increases, Bloomberg reports, citing government documents.

Novo Nordisk’s blockbuster obesity drug Wegovy is set to be greeted by physician enthusiasm and "swift" adoption as it taps into a new liver disease market in the U.S. | Wegovy's mechanism of action ...

Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...

Eli Lilly partners with JD Health to expand in China’s obesity drug market, leveraging digital platforms for growth.

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

The FDA has approved the first generic GLP-1 specifically indicated for weight loss, according to a press release from Teva Pharmaceuticals. As Healio previously reported, Teva Pharmaceuticals ...